Respiration Validation for CPM Device

Cardiopulmonary Disease Clinical Trial

Official title:

Clinical Validation Study for Noninvasive Cardiopulmonary Management Device

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05445492
• Other study ID #: Resp CPM Validation Clayton
• Status: Completed
• Phase: N/A
• Start date: June 22, 2022
• Est. completion date: August 11, 2022

Study information

• Verified date: May 2024
• Source: Analog Device, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to be a clinical validation study to ready the CPM System for FDA 510(k) submission. This study will be conducted as a prospective non-randomized. The study is non-significant risk since the CPM Device is noninterventional and noninvasive. The study is primarily designed to validate the accuracy of the respiration rate and the changes in relative tidal volume. All participants will be fitted with both the CPM Device as well as reference devices (capnography and ECG). Participants will be randomized between 4 procedures (A-D) which will determine the order of 10 exercises. Each exercise has about 2 minutes of device recording and two minutes of rest. Each exercise contains two positions: sitting up for one minute and lying down for one minute. For some exercises, the participant will be instructed to breathe at a certain rate (assisted by a metronome). For other exercises, the participants will breathe at a normal rate but change how deep the are breathing. For the last, all capnography reference devices will be removed, and an ECG reference device will be placed. After exercise 18, the participant will have all devices removed and the study visit will terminate. The participant will receive a safety follow-up call about 1 week after their visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: August 11, 2022
• Est. primary completion date: August 4, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults over the age of 18 and who are willing and able to give informed consent

• Willing and able to participate in all activities related to this study, including trimming chest hair and wearing a reference device and the CPM wearable device

• Volunteers of any race, any gender

• Range of physiques

• Healthy

Exclusion Criteria:

• Injury or skin disturbance in the area of the test device

• Allergies or sensitivities to silicone/acrylic-based adhesive

• Pregnant

• Currently smokes cigarettes

• Has known respiratory conditions that might prevent them from following the study procedure such as:

• Flu

• Pneumonia/bronchitis

• Shortness of breath/respiratory distress

• Respiratory or lung surgery

• Emphysema, COPD, lung disease

• Has self-reported heart or cardiovascular conditions such as chest pain, AFib, CHF, cardiomyopathy, or other conditions that could interfere with cardiopulmonary function

• Has other self-reported health conditions that could interfere with the breathing patterns and exercises detailed in the protocol (including wearing a capnography mask)

Related Conditions & MeSH terms

• Cardiopulmonary Disease
• Pulmonary Heart Disease

Intervention

Device:
• CPM Device
The CPM device and reference device are used simultaneous to validate the CPM device.

Locations

Country	Name	City	State
United States	Clayton Sleep Institute	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Analog Device, Inc.	Clayton Sleep Insititute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Accuracy of CPM System Calculated RR Versus Reference Device Via Percent of Error Accuracy of Respiration Rate	Percentage of respiration rate error within ± 2bpm. Acceptance criteria for clinical utility is >= 85%. The percentage of respiration rate within ± 2brpm was calculated by data points, regardless of its rate and breathing condition, which the CPM System did not screen, therefore reporting the numeric values. Each data point will produce binary result (True or False) if the error is within ± 2 brpm. Assuming this binary result follows a binominal distribution, its confidence interval is also calculated.	90 minutes
Primary	Root Mean Squared Error (RMSE) of Respiration Rates From the CPM System vs Reference Device for Metronome Guided Breathing and Non-metronome Guided Breathing.	First, the subject-specific linear fitting is performed after taking the natural log of both CPM's rTV and reference TV. Then, the residual errors in rTV after the fitting were calculated. Finally, all subject's residual errors are pooled together to calculate the root mean squared (RMS) residual relative errors. The confidence interval was calculated assuming the square of this error follows Chi-square distribution. This error characterized in a log-log domain is converted back to characterize a relative accuracy by taking an exponential of natural constant followed by subtraction of one. The RMS of residual error in % is characterized in this way because the linear fitting in the log-log domain and its residual errors represents faithful relative residual error regardless of an absolute value of TV.	90 minutes
Secondary	Performance of CPM System's ECG by % of CPM ECG Strip Equivalent to Lead II Strip	Performance of CPM System's ECG is measurement by comparing CPM System ECG metrics to the reference device Lead II ECG strip. Clinicians reviewed the criteria below and decided if the CPM strip had equivalence to the Lead II strip.	device measurement (3 minutes)
Secondary	ECG Accuracy Confirmation Comparing CPM Systems Generated ECG Metrics and Reference Lead II Generated ECG Metrics	Determine the accuracy of CPM System's ECG metrics to the reference device. Results are displayed as mean error with standard deviation of error.	device measurement (3 minutes)